This article was created with Dr. Norman Winn Seay, a nephrologist at the Nephrology Clinic at The Kirklin Clinic of UAB Hospital. This article was edited by Elizabeth Hyska.
Chronic kidney disease, often called CKD, is more common than many people realize. In the United States, the prevalence of early- stage CKD increased from approximately 9% of adults in 1999-2000 to nearly 13% by 2017-2018. Alarmingly, close to 90% of individuals with CKD remain unaware of their diagnosis. This is largely because early kidney disease often causes no symptoms.
At the same time, obesity has become increasingly common. More than 40% of U.S. adults have obesity, a condition that affects far more than body weight alone. Obesity can place added stress on the heart, blood vessels, metabolism, and kidneys.
For patients and clinicians, the important point is this: obesity is not only linked to kidney disease through high blood pressure and diabetes. It can also affect the kidneys directly.
What Is Chronic Kidney Disease?
CKD means the kidneys have had signs of damage or reduced function for at least three months. Diagnosis is typically based on one or both of the following criteria:
- Reduced kidney function, reflected by an estimated glomerular filtration rate (eGFR, or an estimate of how well the kidneys are filtering blood) of <60 mL/min/1.73 m².
- Markers of kidney damage, most commonly albuminuria (urine albumin-to-creatinine ratio ≥30 mg/g, i.e. protein leaking into the urine, an early sign of kidney stress), but also including abnormalities seen on urine testing, kidney imaging, or, in selected cases, kidney biopsy.
CKD staging uses both kidney function and urine protein levels because together they help predict the risk of kidney failure, heart disease, and other complications.
Why Kidney Function Often Changes With Age
Kidney function can gradually decline with age. In many people, this change is slow. But when obesity, high blood pressure, diabetes, or inflammation are also present, the kidneys may be more likely to lose function over time.
In adults aged 75 years and older, distinguishing age-related decline from pathologic CKD can be challenging. However, older adults with obesity are particularly vulnerable. Obesity can add extra stress by increasing inflammation, blood pressure, insulin resistance, and the workload on the kidneys.
This is especially important because even mild kidney disease can raise the risk of heart attack, stroke, heart failure, frailty, and death. For a cardiologist, CKD is not just a kidney issue. It is also a major cardiovascular risk factor.
How Obesity Can Harm the Kidneys
Obesity contributes to kidney disease through multiple, interrelated mechanisms that extend well beyond its association with hypertension and type 2 diabetes mellitus.
Hemodynamic and Neurohormonal Activation: Kidneys Must Work Harder
Obesity is characterized by increased sympathetic nervous system activity and chronic activation of the renin–angiotensin–aldosterone system (RAAS). These pathways promote sodium retention, systemic and intraglomerular hypertension, and glomerular hyperfiltration. Over time, sustained hyperfiltration leads to glomerular injury, proteinuria, and progressive nephron loss.
Visceral and Perirenal Adiposity: Fat Around Organs Affect Kidneys
Excess visceral fat, including fat surrounding the kidneys, is metabolically active. Perirenal and renal sinus fat secrete adipokines and pro-inflammatory cytokines that exert local (paracrine) effects on the kidney. These mediators promote inflammation and scarring inside the kidney.
Adipokines and Inflammation: Inflammation Leads to Kidney Scarring
Fat tissue is not just stored energy. It releases chemical signals that can increase inflammation and promote scarring in organs, including the kidneys. In obesity, higher levels of leptin and lower levels of adiponectin may contribute to this inflammatory environment. Over time, these changes can damage the kidney’s filtering units and surrounding tissue.
Interaction with Hypertension and Diabetes: Blood Pressure and Diabetes Add to Risk
Obesity markedly increases the risk of hypertension and type 2 diabetes mellitus, the two leading causes of CKD. When combined, these conditions synergistically accelerate kidney damage through mechanisms that include advanced glycation end products, microvascular injury, and heightened RAAS activation. Importantly, obesity can cause CKD even in the absence of overt diabetes, underscoring its role as an independent renal risk factor.
Why Chronic Kidney Disease Matters for the Heart
CKD and cardiovascular disease are closely connected. When kidney function declines or protein appears in the urine, the risk of heart attack, stroke, heart failure, abnormal heart rhythms, and cardiovascular death rises.
In more advanced CKD (stages 4–5), the cardiovascular risk becomes even more serious. Patients may develop left ventricular hypertrophy, vascular calcification, electrolyte problems, and a higher risk of sudden cardiac death. In many patients, cardiovascular complications become as important as, or even more immediate than, the risk of progressing to dialysis.
That is why kidney protection and heart protection should be treated as part of the same strategy.
Treatment: Protecting the Kidneys and the Heart
Management of CKD in the context of obesity requires a comprehensive, multimodal approach aimed at slowing kidney disease progression while reducing cardiovascular risk.
Lifestyle Interventions
For many patients, weight loss, improved diet quality, regular physical activity, and reduced sodium intake can lower blood pressure, improve insulin sensitivity, reduce kidney workload, and lower urine protein. These changes should be individualized, especially for older adults or people with advanced CKD.
RAAS Inhibition
Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are commonly used in patients with CKD and albuminuria because they reduce pressure inside the kidney’s filters and slow disease progression.
Mineralocorticoid Receptor Antagonists (MRAs)
Mineralocorticoid receptor antagonists, or MRAs, can help selected patients by blocking aldosterone-related inflammation and scarring. Finerenone, a nonsteroidal MRA, has demonstrated kidney and cardiovascular benefit in patients with CKD and type 2 diabetes, though potassium levels still require monitoring. Steroidal MRAs such as spironolactone may also be used in selected patients, particularly for resistant hypertension or heart failure.
SGLT2 Inhibitors
Sodium–glucose cotransporter 2 (SGLT2) inhibitors have changed the treatment of CKD. Originally developed for diabetes, they have been shown to slow kidney disease progression and reduce heart failure risk in many patients, including some without diabetes. In the EMPA-KIDNEY trial, empagliflozin reduced the risk of kidney disease progression or cardiovascular death compared with placebo in patients with CKD, including many without diabetes. The primary outcome occurred in 13.1% of patients taking empagliflozin compared with 16.9% taking placebo.
GLP-1 and Dual Incretin Therapies
Glucagon-like peptide-1 (GLP-1) receptor agonists are especially relevant for patients with obesity, type 2 diabetes, and CKD. These medications can support weight loss, improve blood sugar control, reduce cardiovascular risk, and may help slow kidney disease progression. In the FLOW trial, semaglutide reduced major kidney disease events by 24% in patients with type 2 diabetes and CKD, along with reductions in major cardiovascular events and death from any cause.
A newer medication, tirzepatide, may also help protect kidney function in certain high-risk patients. In the SURPASS-CVOT trial, researchers compared tirzepatide with dulaglutide, another injectable diabetes medication, in people with type 2 diabetes and established cardiovascular disease. Tirzepatide was associated with a lower risk of major kidney events and a slower decline in kidney function compared with dulaglutide, particularly among patients at higher kidney risk. The main tradeoff was that nausea, vomiting, and diarrhea were more common with tirzepatide. Because these kidney outcomes were part of a prespecified exploratory analysis, the findings are encouraging but should be interpreted as hypothesis-generating rather than definitive.
Medication choices should be individualized based on kidney function, urine protein levels, diabetes status, cardiovascular history, side effects, and patient goals.
Conclusion
Obesity matters for kidney health because it can place direct stress on the kidneys, worsen blood pressure and diabetes, and increase inflammation throughout the body. Chronic kidney disease, in turn, greatly increases cardiovascular risk.
The goal is not blame. The goal is early recognition. For people with obesity, diabetes, high blood pressure, or cardiovascular disease, routine blood and urine testing can help detect CKD before symptoms appear. When CKD is found early, clinicians can use lifestyle changes and evidence-based medications to help protect the kidneys, reduce cardiovascular risk, and improve long-term health.
Leave a Reply